Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Giglio

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
JAMA Oncology|November 17, 2022
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort TrialLinda M Liau, Keyoumars Ashkan, Steven Brem, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
JAMA Oncology|November 17, 2022
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort TrialLinda M Liau, Keyoumars Ashkan, Steven Brem, et al.
Pageof 9